Detalles de la búsqueda
1.
In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022).
Antimicrob Agents Chemother
; 68(2): e0113223, 2024 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38205999
2.
In vitro development of resistance against antipseudomonal agents: comparison of novel ß-lactam/ß-lactamase inhibitor combinations and other ß-lactam agents.
Antimicrob Agents Chemother
; 68(5): e0136323, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526050
3.
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Antimicrob Agents Chemother
; 68(5): e0158423, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526046
4.
Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex.
Clin Infect Dis
; 76(Suppl 2): S166-S178, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37125466
5.
New boronate drugs and evolving NDM-mediated beta-lactam resistance.
Antimicrob Agents Chemother
; 67(9): e0057923, 2023 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37650617
6.
Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020).
Antimicrob Agents Chemother
; 67(4): e0152522, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36877017
7.
In vitro potency of xeruborbactam in combination with multiple ß-lactam antibiotics in comparison with other ß-lactam/ß-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum ß-lactamase-producing Enterobacterales.
Antimicrob Agents Chemother
; 67(11): e0044023, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37800963
8.
Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 µg/mL), a Novel ß-Lactam/ß-Lactamase Inhibitor Combination.
J Clin Microbiol
; 61(7): e0165722, 2023 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395644
9.
In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.
J Antimicrob Chemother
; 78(6): 1406-1414, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37042351
10.
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
Eur J Clin Microbiol Infect Dis
; 42(4): 453-459, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36810724
11.
Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity.
Mycoses
; 66(10): 854-868, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37431241
12.
Design, synthesis, and structure-activity relationships of diindolylmethane derivatives as cannabinoid CB2 receptor agonists.
Arch Pharm (Weinheim)
; 356(3): e2200493, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36437108
13.
In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020).
Antimicrob Agents Chemother
; 66(10): e0121422, 2022 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36169327
14.
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019).
Antimicrob Agents Chemother
; 66(2): e0166721, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34807761
15.
Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019.
Antimicrob Agents Chemother
; 66(1): e0139721, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633850
16.
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
J Clin Microbiol
; 60(4): e0244921, 2022 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35249367
17.
In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized ß-lactamase genes.
J Antimicrob Chemother
; 77(3): 689-694, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34849977
18.
Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin.
J Antimicrob Chemother
; 78(1): 185-195, 2022 12 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36329639
19.
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.
J Antimicrob Chemother
; 77(8): 2053-2073, 2022 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35703391
20.
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
J Antimicrob Chemother
; 77(9): 2522-2531, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781341